This website uses cookies to ensure you get the best experience on our website.
- Table of Contents
LIMK1 / LIM domain kinase 1 · IHC design guide
Design Immunohistochemistry for LIMK1
Use the catalog antibody at 1:50–1:200 for chromogenic IHC on paraffin sections (datasheet: A01323). Compare high staining in cerebral cortex neurons with undetected staining in skeletal muscle myocytes (HPA tissue IHC), and account for the antibody’s LIMK1/2 recognition (datasheet: A01323).
Evidence assembled Oct 2026 · For research use; verify linked source records and product datasheet before use
LIMK1 Immunohistochemistry Experimental Design Guide
Expected localisation, validated protocols, controls and antibodies — the at-a-glance facts below, then the full design guide.
Must know before staining
| Expected localisation | Cytoplasm and nucleus (HPA tissue IHC) | |
| Staining pattern | Cytoplasmic and nuclear staining in most tissues (HPA tissue IHC) | |
| Antigen retrieval | Tris-EDTA pH 9.0 HIER, 95–98 °C, 20 min (rule: nuclear antigen) | |
| Positive control | Appendix+4 more · see all | |
| Negative control | Skeletal muscle |
Important caveats
Reasons your staining may differ from the expected pattern.
| Fixation | Keep formalin fixation consistent across samples. (standard IHC practice; not target-specific) | |
| Caveat | The catalog antibody recognizes LIMK1/2 (datasheet: A01323) | |
| Regulation | Highest expression in nervous system (UniProt) | |
| Isoform / epitope | 4 isoforms; check epitope coverage (UniProt) |
Section 1
Recommended LIMK1 IHC & IF Protocols
The catalog antibody’s IHC-P protocol (datasheet) appears alongside three published LIMK1 IHC protocols (PMC7176864; PMC5768095; PMC8020211).
| Sample | Paraffin-embedded human breast carcinoma tissue; fixative not specified (datasheet A01323) |
| Fixation | Image fixative and duration unreported (datasheet A01323); verify before use. |
| Sectioning | 4–5 µm sections on charged slides (standard) |
| Deparaffinisation | Xylene, graded ethanol series to water (standard) |
| Antigen retrieval | Heat-induced epitope retrieval in Tris-EDTA buffer, pH 9.0, 20 min at 95–98 °C (standard rule: nuclear antigen) |
| Peroxidase block | 3% H2O2, 10 min, room temperature (standard) |
| Blocking | 10% normal serum of the secondary host, 30 min, room temperature (standard) |
| Primary antibody | Rabbit anti-LIMK1, 1:50-1:200 (datasheet A01323) |
| Primary incubation | Overnight at 4 °C (standard) |
| Detection | HRP-polymer secondary, DAB chromogen 5–10 min (standard) |
| Counterstain | Hematoxylin, blue, dehydrate and mount (standard) |
| Expected result | LIMK1-positive staining in glandular cells of appendix (HPA tissue IHC: High). HPA tissue profile: Cytoplasmic and nuclear expression in most tissues. No signal in the no-primary control. |
💡Decision noteStart with Tris-EDTA HIER at pH 9.0, 95–98 °C for 20 min (page antigen-retrieval setting); compare the published retrieval conditions if staining needs optimization.
Section 2
What Is the Expected LIMK1 Staining Pattern?
LIMK1 staining should be predominantly cytoplasmic, with nuclear staining possible (UniProt P53667 localisation; HPA: cytoplasmic and nuclear expression in most tissues). Look for strong signal in cerebral cortex neurons, cerebellar molecular-layer cells, and several epithelial or glandular cell populations (HPA: High). LIMK1 has no transmembrane segment (UniProt P53667 topology). HPA rates its tissue IHC profile Approved, with medium consistency between staining and RNA data (HPA: reliability).
| Clear cytoplasmic staining, sometimes accompanied by nuclear staining, in the expected cells. | This fits the reported tissue pattern (HPA: cytoplasmic and nuclear expression in most tissues). Cytoplasm should generally predominate (UniProt P53667 localisation). Assess the cell population as well as the compartment: cerebral cortex neurons and bronchial respiratory epithelial cells are examples with High HPA staining (HPA: tissue IHC). |
| Predominantly crisp cell-surface staining, with little cytoplasmic or nuclear signal. | Treat this as an unexpected compartment pattern and investigate an artefact or off-target signal. LIMK1 has no transmembrane segment (UniProt P53667 topology), while the reported tissue pattern is cytoplasmic and nuclear (HPA: tissue IHC). Nuclear signal alone is not grounds for rejection because both sources permit nuclear localisation (UniProt P53667 localisation; HPA: tissue IHC). |
| Strong staining in skeletal myocytes, especially if the expected positive cells are unstained. | Check for cross-reactivity or endogenous detection activity before assigning the signal to LIMK1 (general IHC practice). HPA reports skeletal myocytes as Not detected by tissue IHC (HPA: skeletal muscle), although UniProt reports lower expression in skeletal muscle than in the nervous system (UniProt P53667 tissue specificity). That distinction makes an isolated strong result worth checking, rather than conclusive evidence of a false positive. |
| Diffuse colour across tissue, empty spaces, or many unrelated cell populations. | Interpret localisation only after background is controlled (general IHC practice). Widespread colour that obscures cell borders and nuclei cannot reliably establish the cytoplasmic and nuclear distribution reported for LIMK1 (HPA: tissue IHC). Review blocking, washes, antibody concentration, and the detection control as general chromogenic IHC checks. |
| No convincing staining in a cerebral cortex section with identifiable neuronal cells. | A negative result in that comparison tissue is unexpected: HPA reports High staining in cerebral cortex neurons, and UniProt reports its highest adult brain expression in cerebral cortex (HPA: cerebral cortex; UniProt P53667 tissue specificity). First check tissue preservation and the general IHC workflow. An absent signal alone does not identify which step failed. |
💡Expected LIMK1 appearanceCall a result consistent with LIMK1 when clear, predominantly cytoplasmic staining, with possible nuclear staining, occurs in a High-rated cell population such as cerebral cortex neurons (UniProt P53667 localisation; HPA: cerebral cortex); dominant cell-surface colour or equally strong diffuse background is suspect (UniProt P53667 topology; general IHC practice).
| Tissue and cell choice | For a positive comparison, use a reported High population, such as cerebral cortex neurons or bronchial respiratory epithelial cells (HPA: tissue IHC). Skeletal myocytes are reported Not detected and offer a contrasting population (HPA: skeletal muscle). These are observed staining levels, not guaranteed outcomes with every section or antibody. |
| Compartment and topology | Expect predominantly cytoplasmic localisation, with nuclear and cytoskeletal localisation also reported (UniProt P53667 localisation). HPA describes cytoplasmic and nuclear tissue expression (HPA: tissue IHC). The absence of a transmembrane segment makes a dominant cell-surface outline difficult to reconcile with the supplied target record (UniProt P53667 topology). |
| Strength of the tissue evidence | HPA labels the tissue IHC profile Approved and describes medium consistency between antibody staining and RNA expression; external characterization supports staining (HPA: reliability). Both listed antibodies are IHC Approved (HPA: HPA028516, HPA073571). Use the reported pattern as a comparison, while checking unexpected staining with controls. |
| Which pattern applies to IF/ICC? | For IF/ICC, HPA reports supported localisation to nuclear speckles and cytosol (HPA: subcellular). HPA lists ICC support for HPA028516; no ICC status is supplied for HPA073571 (HPA: antibody validation). Nuclear speckles are an IF/ICC observation and should not be required as a distinct feature in chromogenic tissue IHC. |
| Epitope and isoform limits | UniProt lists four LIMK1 isoforms and LIM, PDZ, and kinase domains (UniProt P53667 isoforms and domains). The supplied evidence gives no antibody epitope or isoform coverage, so it cannot predict whether a particular isoform will stain. Likewise, it gives no target-specific fixation sensitivity or antigen-retrieval requirement. |
| Situation | Likely cause | Next action |
|---|---|---|
| No signal in a reported High cell population. | The comparison conflicts with reported staining, but does not identify a failed step (HPA: cerebral cortex neurons, High). | Check that the expected cells are present, then review antibody application, retrieval, detection, and counterstaining as general IHC workflow checks. Compare a same-run positive control before interpreting the section as LIMK1-negative. |
| Strong staining appears only in skeletal myocytes. | HPA reports skeletal myocytes as Not detected by tissue IHC (HPA: skeletal muscle); cross-reactivity or endogenous detection activity is possible (general IHC practice). | Compare a reported High population and inspect a detection control without primary antibody. Review the signal's cellular distribution before assigning it to LIMK1. |
| Cell surfaces dominate the staining. | That distribution differs from the reported cytoplasmic and nuclear tissue pattern (HPA: tissue IHC) and the no-transmembrane topology (UniProt P53667 topology). | Recheck localisation against a positive comparison section and a detection control. If cell-surface colour persists without matching intracellular signal, treat target attribution as uncertain. |
| Diffuse chromogen obscures the cells. | Background can prevent a reliable compartment call (general IHC practice). | Review blocking, washes, primary antibody concentration, and detection timing as general IHC checks. Reassess whether cytoplasm and nuclei can be distinguished before scoring the LIMK1 pattern. |
| Nuclear staining is present alongside cytoplasmic staining. | Both compartments are reported in tissue IHC (HPA: tissue IHC), although cytoplasmic localisation predominates in UniProt (UniProt P53667 localisation). | Evaluate whether the signal follows the expected cell population and has manageable background. Do not reject the section solely because nuclei stain; compare compartment balance with the positive tissue. |
| Results vary between antibody preparations or sections. | The supplied record does not establish epitope coverage or target-specific fixation sensitivity; HPA describes only medium staining-to-RNA consistency (HPA: reliability). | Compare matched tissue and cell populations, include same-run controls, and record retrieval and detection conditions as general IHC practice. Avoid attributing the difference to LIMK1 epitope masking without supporting evidence. |
Experiment evidence
IHC & IF images showing LIMK1 staining
A01323 · IHCImmunohistochemistry (IHC) analyzes of LIMK1/2 (D402) pAb in paraffin-embedded human breast carcinoma tissue at 1:100.
HPA · Cerebral cortexHuman Protein Atlas IHC, Cerebral cortex. Source: https://www.proteinatlas.org/ENSG00000106683-LIMK1/tissue/cerebral+cortex#imid_8029839
HPA · StomachHuman Protein Atlas IHC, Stomach. Source: https://www.proteinatlas.org/ENSG00000106683-LIMK1/tissue/stomach+1#imid_8029723
HPA · ColonHuman Protein Atlas IHC, Colon. Source: https://www.proteinatlas.org/ENSG00000106683-LIMK1/tissue/colon#imid_8029765
HPA · LiverHuman Protein Atlas IHC, Liver. Source: https://www.proteinatlas.org/ENSG00000106683-LIMK1/tissue/liver#imid_8029750
HPA · ICC-IF A-431Human Protein Atlas immunofluorescence, A-431, antibody HPA028516; green = LIMK1, blue = nucleus, red = microtubules.
HPA · ICC-IF A-431Human Protein Atlas immunofluorescence, A-431, antibody HPA028516; green = LIMK1, blue = nucleus, red = microtubules.
← swipe / scroll for more images →
Real IHC / IF data behind the staining-pattern expectations in this section.
Sample controls for LIMK1 IHC & IF
🧪Run breast first: glandular cells should stain (HPA: High in breast glandular cells). Use skeletal muscle myocytes as the negative tissue (HPA: Not detected in skeletal muscle myocytes); on the breast slide, assess non-glandular cells for background relative to glandular cells rather than assuming they are target-free (HPA: High is assigned to glandular cells).
Positive control tissue: Appendix (Glandular cells, HPA High)
Negative control tissue: Skeletal muscle (HPA Not detected)
ICC-IF cell lines (HPA subcellular resource): HPA ICC-IF images show LIMK1 in A-431, U-251MG, U2OS, with annotated localisation: Nuclear speckles (supported), Cytosol (supported) (HPA subcellular).
Technical controls: Include a no-primary, secondary-only control and a host-species-matched nonimmune IgG control appropriate to the polyclonal primary (catalog caption: pAb). Use LIMK1 knockout tissue or cells as a biological specificity control, while checking for residual LIMK2 staining because the caption identifies the reagent as LIMK1/2 (catalog caption: LIMK1/2); quench endogenous peroxidase for chromogenic detection (standard IHC practice).
⚠️Feasibility: No target-specific fixation window or fixation effect is reported in the supplied evidence, and the fixative is unreported in the paraffin-section caption (catalog caption: paraffin-embedded breast carcinoma; fixative not stated). Antigen retrieval requirements are unreported; optimize retrieval empirically for IHC on paraffin sections (standard IHC practice). The supplied evidence does not establish that frozen sections or IF are easier; interpret breast carcinoma staining with attention to tissue background and the reagent’s stated LIMK1/2 recognition (catalog caption: LIMK1/2 in breast carcinoma).
HPA tissue IHC evidence for LIMK1
Comprehensive Human Protein Atlas IHC scoring per tissue (reliability: Approved — Medium consistency between antibody staining and RNA expression data. External characterization data supports antibody staining.). Rows are taken directly from the HPA tissue chart — click any row's HPA link to view the source.
Positive expression · recommended positive controls
| Tissue | Cell type | Level | Evidence | Source |
|---|---|---|---|---|
| Appendix | Glandular cells | High | Protein (IHC) | HPA → |
| Breast | Glandular cells | High | Protein (IHC) | HPA → |
| Bronchus | Respiratory epithelial cells | High | Protein (IHC) | HPA → |
| Cerebellum | Cells in molecular layer | High | Protein (IHC) | HPA → |
| Cerebral cortex | Neuronal cells | High | Protein (IHC) | HPA → |
Undetected expression · recommended negative controls
| Tissue | Cell type | Level | Evidence | Source |
|---|---|---|---|---|
| Skeletal muscle | Myocytes | Not detected | Protein (IHC) | HPA → |
Section 3
Advanced LIMK1 IHC Tips
Troubleshoot LIMK1 staining in paraffin sections by checking retrieval, compartment, cell type and antibody specificity before comparing chromogenic signals.
How should I retrieve LIMK1 in paraffin sections when nuclear staining is weak?
Start with Tris-EDTA pH 9.0 heat-induced epitope retrieval at 95–98 °C for 20 min (page retrieval setting). Keep section thickness, heating vessel and cooling time consistent across runs so differences in nuclear and cytoplasmic signal remain interpretable (standard IHC practice). Examine an expected positive cell population, such as cerebral cortex neuronal cells, alongside a primary-antibody omission control (HPA: High in cerebral cortex neuronal cells; standard IHC practice). If staining remains weak, compare a shorter heating time on adjacent sections before changing buffer chemistry, since excessive retrieval can damage tissue morphology (standard IHC practice). The paraffin-section caption documents staining at 1:100 with SKU A01323 but does not report its retrieval conditions (caption: A01323).
Could fixation explain weak LIMK1 staining in paraffin sections?
Target-specific fixation sensitivity is unknown from the supplied evidence; the paraffin-section image caption does not state a fixative (caption: A01323). Record the fixative, fixation duration and processing schedule for each specimen, then compare sections processed together before attributing a weak signal to LIMK1 biology (standard IHC practice). Assess tissue morphology and compare nuclear and cytoplasmic staining in an expected positive cell population, such as breast glandular cells (HPA: High in breast glandular cells; HPA: cytoplasmic and nuclear expression). If fixation varies between specimens, use matched positive controls and repeat the page’s Tris-EDTA pH 9.0 retrieval for 20 min before comparing scores (page retrieval setting; standard IHC practice).
Which LIMK1 staining compartments should count as plausible in tissue IHC?
Score cytoplasmic and nuclear staining separately, because tissue IHC reports both compartments in most tissues (HPA: cytoplasmic and nuclear expression). Predominantly cytoplasmic localisation, with possible nuclear and cytoskeletal distribution, is consistent with the protein record (UniProt P53667: subcellular localisation). Lamellipodial enrichment has a stated dependence on CDC42BPA, CDC42BPB and FAM89B/LRAP25, so absence of that pattern in a section does not by itself invalidate staining (UniProt P53667: subcellular localisation). Assess staining within intact cells against the counterstain and a primary-antibody omission control, rather than counting diffuse extracellular colour as cellular signal (standard IHC practice). Nuclear speckles are supported in ICC/IF images, but chromogenic tissue sections may not resolve them reliably (HPA: supported nuclear speckles and cytosol; standard IHC practice).
Can this stain distinguish LIMK1 isoforms or exclude LIMK2?
The record lists 4 LIMK1 isoforms, but the supplied evidence gives no antibody epitope sequence or isoform coverage (UniProt P53667: isoforms; supplied antibody evidence). The selected image identifies its reagent as LIMK1/2 (D402) pAb, so its tissue colour should not be interpreted as LIMK1-specific without additional validation (caption: A01323). Request an epitope map and check whether the recognized sequence is retained in each isoform before assigning isoform-specific staining (standard IHC validation practice). LIMK1 contains two LIM domains, a PDZ domain and a protein kinase domain, making epitope position relevant to such an assessment (UniProt P53667: domains). Compare antibody staining with an independently validated LIMK1-specific control if isoform or paralog attribution is essential (standard IHC validation practice).
How can IF help verify the cell and compartment behind an IHC signal?
Use the separate IF/ICC workflow to costain LIMK1 with a validated marker for the cell population being examined; for cerebral cortex, the tissue IHC reference identifies neuronal cells as High (HPA: High in cerebral cortex neuronal cells; standard IF practice). Choose fluorophores and filter sets after checking tissue autofluorescence, especially when a weak channel overlaps broad background emission (standard IF practice). LIMK1 has no transmembrane segment and is found in the cytosol and nuclear speckles, so permeabilise fixed cells sufficiently for intracellular and nuclear epitope access (UniProt P53667: topology; HPA: supported cytosol and nuclear speckles; standard IF practice). Include single-channel and primary-antibody omission controls to assess bleed-through and nonspecific fluorescence (standard IF practice). Treat the paraffin-section caption as IHC evidence only, since it reports no IF/ICC conditions (caption: A01323).
What should I check when LIMK1 IHC has widespread brown background?
Run a primary-antibody omission section to distinguish detection-system background from antibody-dependent staining (standard IHC practice). For a peroxidase and DAB workflow, verify endogenous peroxidase blocking and inspect pigment or precipitate under the counterstain before calling brown deposits positive (standard chromogenic IHC practice). Titrate the primary antibody and optimise protein blocking and washes; 1:100 is documented only for the selected A01323 paraffin-section image, not as a universal dilution (caption: A01323; standard IHC practice). Compare intact cells with a low-staining reference such as skeletal-muscle myocytes, while accounting for tissue processing and cell-type differences (HPA: Not detected in skeletal-muscle myocytes; standard IHC practice). Widespread cytoplasmic or nuclear signal can be plausible, so judge background by cellular boundaries and controls rather than distribution alone (HPA: cytoplasmic and nuclear expression in most tissues; standard IHC practice).
How should I quantify LIMK1 staining across comparable tissue sections? ⚠ ANSWER MARKED FOR VERIFICATION
Define the cell population and region before scoring, then report nuclear and cytoplasmic compartments separately (HPA: cytoplasmic and nuclear expression; standard IHC scoring practice). An H-score combines the percentage of cells at each intensity into a 0–300 scale; alternatively report percentage positive cells or positive-cell density per mm² (standard IHC scoring practice). Normalise counts to the number of eligible intact cells, or density to measured viable tissue area, and exclude folds, edges and necrosis using the same rules across specimens (standard IHC scoring practice). Keep retrieval, antibody dilution, chromogen development and image-analysis thresholds constant when comparing specimens (standard IHC practice). Report the exact antibody identity because the selected A01323 image describes a LIMK1/2 reagent, which limits LIMK1-specific interpretation (caption: A01323).
How do I distinguish genuine LIMK1 staining from tissue artefacts?
A plausible positive pattern is cell-associated cytoplasmic and sometimes nuclear signal in intact tissue cells, consistent with reported LIMK1 localisation (HPA: cytoplasmic and nuclear expression; UniProt P53667: subcellular localisation). Check expected cell populations, including High neuronal cells in cerebral cortex, against a same-run negative control (HPA: High in cerebral cortex neuronal cells; standard IHC practice). Treat staining confined to section edges, folds, necrotic material or extracellular deposits as suspect, especially if it appears on the primary-antibody omission section (standard IHC practice). In peroxidase and DAB staining, residual endogenous enzyme activity can also create brown signal, so review the block and control section (standard chromogenic IHC practice). Because the selected image uses a LIMK1/2 reagent, a convincing tissue pattern alone cannot establish LIMK1-specific signal (caption: A01323).
Boster reagents
Best LIMK1 / LIM domain kinase 1 IHC Antibodies
A01323 has real IHC data from paraffin-embedded human breast carcinoma (A01323 IHC image caption). Its listed reactivity covers human, mouse and rat (A01323 catalog reactivity).
Real IHC data
Anti-LIMK1/2 (D402) Antibody
Cat # A01323
A01323 is the sole card and lists IHC among its applications (A01323 catalog applications). Its image shows paraffin-embedded human breast carcinoma stained at 1:100 (A01323 IHC image caption).
Which to pick: Choose A01323 for paraffin-section IHC based on its human breast carcinoma image; the fixative is unreported (A01323 IHC image caption). No listed SKU has an IF/ICC application or IF image, so there is no validated IF/ICC pick here (A01323 catalog applications and image alts). A01323 is the cross-species candidate because it is listed as reactive with human, mouse and rat, though its IHC image documents only human tissue (A01323 catalog reactivity; A01323 IHC image caption).
Each figure is that product's own IHC / IF validation image from its datasheet.
References
- UniProt Consortium. UniProt entry P53667 (LIMK1_HUMAN, LIM domain kinase 1).
- Human Protein Atlas. LIMK1 tissue IHC expression (reliability: Approved).
- Human Protein Atlas. LIMK1 subcellular location (ICC-IF): Localized to the nuclear speckles and cytosol..
- Human Protein Atlas. LIMK1 antibody validation summary (2 antibodies).
- Up-regulation of LIMK1 expression in prostate cancer is correlated with poor pathological features, lymph node metastases and biochemical recurrence. Journal of cellular and molecular medicine 2020 — PMC7176864.
- LIMK1 Interacts with STK25 to Regulate EMT and Promote the Proliferation and Metastasis of Colorectal Cancer. Journal of oncology 2022 — PMC8901301.
- LIM kinase 1 serves an important role in the multidrug resistance of osteosarcoma cells. Oncology letters 2018 — PMC5768095.
- FOXD3‑AS1/miR‑128‑3p/LIMK1 axis regulates cervical cancer progression. Oncology reports 2021 — PMC8020211.
- PubMed PMID:8183554 — UniProt-cited evidence.
- PubMed PMID:8689688 — UniProt-cited evidence.
- PubMed PMID:8812460 — UniProt-cited evidence.
Immunohistochemistry protocol sheet for LIMK1 (LIM domain kinase 1). Expected localisation Cytoplasm and nucleus (HPA tissue IHC). Antigen retrieval: Tris-EDTA pH 9.0 HIER, 95–98 °C, 20 min (rule: nuclear antigen). Validated IHC antibody: A01323 at 1:50-1:200 (the product's own IHC validation image is shown). Controls (HPA): positive Appendix (Glandular cells); negative Skeletal muscle. IHC-P workflow on paraffin sections; fixative unspecified. Protocol steps: 1. Sample: Paraffin-embedded human breast carcinoma tissue; fixative not specified (datasheet A01323); 2. Fixation: Image fixative and duration unreported (datasheet A01323); verify before use.; 3. Sectioning: 4–5 µm sections on charged slides (standard); 4. Deparaffinisation: Xylene, graded ethanol series to water (standard); 5. Antigen retrieval: Heat-induced epitope retrieval in Tris-EDTA buffer, pH 9.0 , 20 min at 95–98 °C…; 6. Peroxidase block: 3% H2O2, 10 min , room temperature (standard); 7. Blocking: 10% normal serum of the secondary host, 30 min , room temperature (standard); 8. Primary antibody: Rabbit anti-LIMK1, 1:50-1:200 (datasheet A01323); 9. Primary incubation: Overnight at 4 °C (standard). Watch for: Fixation: Keep formalin fixation consistent across samples. (standard IHC practice; not target-specific); Caveat: The catalog antibody recognizes LIMK1/2 (datasheet: A01323); Isoform / epitope: 4 isoforms; check epitope coverage (UniProt); Regulation: Highest expression in nervous system (UniProt). Evidence: UniProt P53667, HPA tissue IHC · Approved, HPA ICC-IF · nuclear speckles and cytosol., Datasheet A01323, PMC7176864, PMC5768095. QR code links to https://www.bosterbio.com/bosterbio-gene-info-cards/LIMK1/immunohistochemistry-ihc-guide.